India Globalization Capital, Inc. (NYSE: IGC) Developing Phytocannabinoid-Based Product Pipeline to Treat Two- and Four-Legged Alike

Looking to gain an advantageous foothold in the burgeoning medical marijuana market, India Globalization Capital, Inc. (NYSE MKT: IGC) is developing innovative cannabis-based combination therapies that have application for both humans and animals. The company’s focus is on treating pain, post-traumatic stress disorder (PTSD), chronic and terminal neurological and oncological diagnoses, cachexia, and other life-altering medical conditions.

IGC continues developing a portfolio of patent filings for phytocannabinoid-based treatments and has filed six patents to date. The company currently has three products in pre-clinical trials: IGC-501 for treatment of neuropathic pain in adult humans, IGC-502 for treatment of seizures in animals, and IGC-504 for treatment of cachexia in humans and animals.

Two of IGC’s patent filings, IGC-502 and IGC-505, are for combination therapies to treat seizures in dogs and cats, which represents a remarkably large market. Statistics show that between one percent and over five percent of dogs in the United States have some kind of seizure disorder. Certain dog breeds with hereditary epilepsy may have up to 15-20 percent incidence of seizures.

IGC’s novel therapy uses cannabinoid extracts in combination with other drugs to treat seizures in both dogs and cats, and this therapy has potential for application in humans, as well. The therapy can be administered through a variety of delivery technologies.

Operating on the belief that expanding cannabis legalization will create explosive demand for cannabinoid-based pharmaceutical therapies and related technologies and services, IGC is racing to be at the head of the pack and to be a first mover in the marijuana space by developing novel therapies, filing patent applications, and acquiring technologies from related industries that can cross over to cannabis as soon as permitted by federal law.

The company largely employs an outsourced model and has formed strategic alliances with doctors and scientists with expertise in central and peripheral nervous system disorders, the FDA process, and in pharmaceutical, nutraceutical and veterinarian trials. IGC also continues seeking information exchanges with medical cannabis dispensaries, doctors, research scientists, biotech companies, and medical and business professionals within the cannabinoid space, placing great value on collaborative research that can aid in the commercialization of products and in locating new ways to help patients — both human and animal — benefit from cannabinoids.

For more information, visit the company’s website at www.IGCinc.us

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html